Certara, Inc.


SKU: CERT-1 Category:


Certara, Inc.: Introduction of Unified Certara Cloud Platform 


Certara reported its first-quarter financial results for 2024, detailing a period of structured progress and proactive initiatives aimed at solidifying and expanding its position in the pharmaceutical software and technology-driven services space. Revenues for the quarter totaled $96.7 million, marking a 7% growth on a reported basis and 6% on a constant currency basis, compared to the prior year. This increment was supported by robust demand for Certara’s biosimulation software and services, complemented by a burgeoning interest in AI-enhanced products after its recent acquisition of Vyasa.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!